Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
Rosario PivonelloMaria FleseriuJohn D Newell-PriceAkira ShimatsuR A FeeldersPinar KadiogluA TabarinThierry BrueEliza B GeerA PiacentiniA M PedroncelliBeverly M K BillerPublished in: Journal of endocrinological investigation (2024)
Improvements in clinical signs and additional specific manifestations of hypercortisolism associated with Cushing's disease occurred alongside decreases in mUFC. Trial registration NCT02180217 (first posted July 2014).